These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 2589763)

  • 1. Audiologic threshold monitoring of patients receiving ototoxic drugs. Preliminary report.
    Meyerhoff WL; Maale GE; Yellin W; Roland PS
    Ann Otol Rhinol Laryngol; 1989 Dec; 98(12 Pt 1):950-4. PubMed ID: 2589763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss.
    de Hoog M; van Zanten BA; Hop WC; Overbosch E; Weisglas-Kuperus N; van den Anker JN
    J Pediatr; 2003 Jan; 142(1):41-6. PubMed ID: 12520253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-frequency pure-tone audiometry in children: a test-retest reliability study relative to ototoxic criteria.
    Beahan N; Kei J; Driscoll C; Charles B; Khan A
    Ear Hear; 2012; 33(1):104-11. PubMed ID: 21760512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Audiologic monitoring for ototoxicity.
    Campbell KC; Durrant J
    Otolaryngol Clin North Am; 1993 Oct; 26(5):903-14. PubMed ID: 8233496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting sensitivity of distortion-product otoacoustic emissions to ototoxic hearing loss.
    Reavis KM; Phillips DS; Fausti SA; Gordon JS; Helt WJ; Wilmington D; Bratt GW; Konrad-Martin D
    Ear Hear; 2008 Dec; 29(6):875-93. PubMed ID: 18753950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of tobramycin on the renal handling of vancomycin.
    Munar MY; Elzinga L; Brummett R; Golper TA; Bennett WM
    J Clin Pharmacol; 1991 Jul; 31(7):618-23. PubMed ID: 1894757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of aminoglycoside ototoxicity by high-frequency auditory evaluation: selected case studies.
    Fausti SA; Rappaport BZ; Schechter MA; Frey RH; Ward TT; Brummett RE
    Am J Otolaryngol; 1984; 5(3):177-82. PubMed ID: 6742338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is intraperitoneal tobramycin ototoxic in CAPD patients?
    Nikolaidis P; Vas S; Lawson V; Kennedy-Vosu L; Bernard A; Abraham G; Izatt S; Khanna S; Bargman JM; Oreopoulos DG
    Perit Dial Int; 1991; 11(2):156-61. PubMed ID: 1854874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distortion-product otoacoustic emissions: a useful test for monitoring ototoxicity induced by pegylated interferon and ribavirin treatment in patients with chronic hepatitis C.
    Casale M; Mazzarelli C; Vespasiani Gentilucci U; Potena M; Pappacena M; Faiella F; Galati G; Salvinelli F; Picardi A
    Int J Immunopathol Pharmacol; 2012; 25(2):551-6. PubMed ID: 22697091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Otoacoustic emissions: an approach for monitoring aminoglycoside-induced ototoxicity.
    Hotz MA; Harris FP; Probst R
    Laryngoscope; 1994 Sep; 104(9):1130-4. PubMed ID: 8072361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency audiometry in prospective clinical research of ototoxicity due to platinum derivatives.
    van der Hulst RJ; Dreschler WA; Urbanus NA
    Ann Otol Rhinol Laryngol; 1988; 97(2 Pt 1):133-7. PubMed ID: 3281541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vancomycin administration in continuous ambulatory peritoneal dialysis: the risk of ototoxicity.
    Gendeh BS; Gibb AG; Aziz NS; Kong N; Zahir ZM
    Otolaryngol Head Neck Surg; 1998 Apr; 118(4):551-8. PubMed ID: 9560111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ototoxicity of tobramycin: a clinical overview.
    Neu HC; Bendush CL
    J Infect Dis; 1976 Aug; 134 Suppl():S206-18. PubMed ID: 1085788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective, randomized comparison of the efficacy and safety of netilmicin-clindamycin and tobramycin-clindamycin in the treatment of serious systemic infections.
    Kahalley S; Chandler J; Hawkins J; Norris G; Waugespack R; Snow RM
    Clin Ther; 1985; 7(4):497-506. PubMed ID: 4016829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective study of adverse reactions associated with vancomycin therapy.
    Sorrell TC; Collignon PJ
    J Antimicrob Chemother; 1985 Aug; 16(2):235-41. PubMed ID: 3934126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vancomycin ototoxicity in patients with normal renal function.
    Mellor JA; Kingdom J; Cafferkey M; Keane C
    Br J Audiol; 1984 Aug; 18(3):179-80. PubMed ID: 6487853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Monitoring drug ototoxicity with distortion products].
    Orts Alborch M; Morant Ventura A; García Callejo J; Ferrer Baixauli F; Martínez Beneito MP; Marco Algarra J
    Acta Otorrinolaringol Esp; 2000; 51(5):387-95. PubMed ID: 11000679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure.
    Robertson CM; Tyebkhan JM; Peliowski A; Etches PC; Cheung PY
    Acta Paediatr; 2006 Feb; 95(2):214-23. PubMed ID: 16449030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Retrospective study on a possible ototoxicity of tobramycin in the newborn infant].
    Giaccai F; Bigozzi M; Salimbeni C; Periti P
    Clin Ter; 1975 Dec; 75(5):479-89. PubMed ID: 1218464
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of netilmicin and tobramycin therapy in patients with renal impairment.
    Gorse GJ; Bernstein JM; Cronin RE; Etzell PS
    Scand J Infect Dis; 1992; 24(4):503-14. PubMed ID: 1411317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.